Therapeutic implications of osteoprotegerin

Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.

Osteosarcoma is the most frequent primary bone malignant tumor that develops mainly in children and adolescents. Despite recent improvements in chemotherapy and surgery, survival rate is approximately 50% after 5 years. Osteoprotegerin (OPG) is a potent inhibitor of osteoclast differentiation and activation, but its use as therapeutic agent in cancer-associated osteolysis remains controversial ...

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

The integrity of the skeleton depends upon bone remodeling, the permanent and controlled resorption of bone by osteoclasts (OC) and its subsequent replacement by bone-forming osteoblasts. An imbalance between bone resorption and bone formation results in osteoporosis (if bone resorption exceeds bone formation) or osteopetrosis (if bone formation exceeds bone resorption). The regulation of the b...

Diagnostic and Therapeutic Implications of Conjoined Nerve Root Anomalies: A Senegalese Study of Three Cases

Background & Aim: Conjoined nerve root is defined as two adjacent nerve roots that share a common dural envelope at some points during their course from the thecal sac. This study reports our experience of conjoined roots involving three cases in Dakar. Methods & Materials/Patients: This is a consecutive study from 2013 to 2015 involving patients supported for disc herniation and who have pr...

Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies Running title: Modified osteoprotegerin for osteolytic malignancies Key words: Osteoprotegerin, TRAIL, RANKL, osteoclast, bone

Osteoprotegerin rich tumor microenvironment: implications in breast cancer

Osteoprotegerin (OPG) is a soluble decoy receptor for tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL). It belongs to the tumor necrosis factor receptor superfamily (TNFRSF). OPG was initially discovered to contribute to homeostasis of bone turnover due to its capability of binding to receptor activator of nuclear factor-kappaB (NF-kB). However, apart from bone turnover, OP...